[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"helicobacter-pylori-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:helicobacter-pylori-infections":445},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,41,65,86,108,130,154,179,203,231,265,288,314,331,354,386,412,431,464,485,505,529,550],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100638382","phase-3-the-clinical-trail-to-evaluate-the-efficacy-and-safety-of-anaprazole-sodium-enteric-coated-tablets-combined-with-bismuth-containing-quadruple-therapy-in-eradicating-helicobacter-pylori-100638382",false,"NCT07606833","The Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadruple Therapy in Eradicating Helicobacter Pylori","A Multicenter, Randomized, Double Blind, Double-simulated, Parallel Control of Positive Drug Phase III Clinical Study Evaluating the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Containing Bismuth in Quadruple Therapy for the Eradication of Helicobacter Pylori","Inclusion Criteria:\n\n1. Aged 18-75 years\n2. During the screening visit, the participants were determined to be Hp-positive by 13C-UBT and Hp eradication therapy was required by the investigator.\n3. Fully understand the content of the experiment, voluntarily participate in the experiment, and sign the informed consent.\n\nExclusion Criteria:\n\n1. Known allergic history to Anaprazole or Esomeprazole, or amoxicillin or clarithromycin and bismuth(including any related excipients ).\n2. Have a history of severe rapid-onset hypersensitivity to β-lactam agents (such as cephalosporins, carbapenems, monocyclic β-lactam).\n3. The participant has Zollinger-Ellison syndrome.\n4. Participants known to have acute upper gastrointestinal bleeding, active gastric or duodenal ulcer, acute gastric mucosal injury (AGML) or acute duodenal mucosal injury (ADML).\n5. Participants in the trial had previously undergone surgeries or procedures that might affect gastric acid secretion or drug absorption.\n6. Participants with a history of malignant tumors within 5 years prior to screening (Cutaneous basal cell carcinoma or cervical carcinoma in situ that has been cured is excluded).\n7. The subject has severe central nervous system, cardiovascular, respiratory, liver, kidney, gastrointestinal, urinary, endocrine or hematological diseases that the investigator believes may affect the study results and the safety of the participants.\n8. Laboratory examination during the screening period showed ALT or AST \\> 2 times of the upper limit of normal value, TBIL \\> 1.5 times of the upper limit of normal value; renal function Cr \\> 1.5 times of the upper limit of normal value (one review was allowed in the study, and those who still did not meet the requirements for inclusion were excluded).\n9. Participants with severe arrhythmia, multigenic premature ventricular contractions (PVC), second-degree or higher atrioventricular block, ventricular arrhythmia or prolonged QT interval (QTcF\\> 450ms in male and 470ms in female).\n10. Previously received Helicobacter pylori eradication treatment.\n11. Used PPI or P-CAB preparations within 2 weeks before 13C-UBT examination during the screening period; Antibiotics, bismuth-containing preparations, or traditional Chinese medicine with antibacterial effects were used within 4 weeks before 13C-UBT test during the screening period.\n12. Those with chronic drug abuse in the 12 months prior to screening.\n13. Those with alcohol dependence in the 12 months prior to screening.\n14. Participated used experimental drugs\u002Fdevices in other drug\u002Fdevice clinical studies within 3 months before screening.\n15. Female participants who are suspected or already pregnant, breastfeeding; and female participant or a partner of male participant who are planning to become pregnant during the study.\n16. Others were deemed unsuitable for the trial .","ALL","18 Years","75 Years",{"count":20,"type":21},556,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a multicenter, randomized, double blind, double-simulated, parallel control of positive drug phase III clinical study to evaluate the efficacy and safety of Anaprazole versus Esomeprazole-containing Bismuth quadruple therapy for eradication of Helicobacter pylori in China.",[27],"HELICOBACTER PYLORI INFECTIONS","NOT_YET_RECRUITING","2026-05-19",{"date":31,"type":32},"2026-05-26","ACTUAL",{"date":34,"type":21},"2026-06-10",{"date":36,"type":21},"2027-03-18",{"name":38,"class":39},"Xuanzhu Biopharmaceutical Co., Ltd.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100639402","phase-3-effect-of-bismuth-add-on-to-dual-therapy-for-helicobacter-pylori-eradication-100639402","NCT07576959","Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication","Effect of Bismuth Add-on to Vonoprazan-Amoxicillin Dual Therapy for Helicobacter Pylori Eradication - A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. Individuals infected with Helicobacter pylori who have not previously undergone eradication therapy.\n2. Individuals willing to receive first-line eradication therapy.\n3. Study participants must be 20 years of age or older.\n\nExclusion Criteria:\n\n1. Individuals with a history of gastrectomy (stomach removal surgery).\n2. Individuals unsuitable to receive the study drug (e.g., history of allergy or severe adverse effects to the study drug).\n3. Pregnant or breastfeeding women.\n4. Individuals with severe acute or chronic diseases, such as renal failure, liver cirrhosis, or incurable malignant tumors.\n5. Patients with chronic hepatitis (AST \\[Aspartate Aminotransferase\\] or ALT \\[Alanine Aminotransferase\\] \\> 100 U\u002FL).\n6. Individuals unwilling to comply with the treatment plan or sign the informed consent form.","20 Years",{"count":50,"type":21},990,[24],"This study aims to compare the efficacy and safety of a bismuth-supplemented 14-day vonoprazan-based dual therapy ( triple therapy) versus a 14-day vonoprazan-based dual therapy without bismuth for first-line H. pylori eradication. Furthermore, the investigators will investigate the impact of these eradication regimens on the gut microbiota, the development of antibiotic resistance, and changes in metabolic syndrome indicators pre- and post-treatment.",[27],"RECRUITING","2026-05-04",{"date":57,"type":32},"2026-05-08",{"date":59,"type":21},"2026-04-08",{"date":61,"type":21},"2032-12-31",{"name":63,"class":64},"National Taiwan University Hospital","OTHER",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100640291","levofloxacin-based-sequential-therapy-versus-bismuth-quadruple-therapy-for-helicobacter-pylori-eradication-100640291","NCT07574983","Levofloxacin-Based Sequential Therapy Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication","Levofloxacin-Based Sequential Therapy Compared With Bismuth-Based Quadruple Therapy for Eradication of Helicobacter Pylori Infection: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 20 years and older\n* Confirmed Helicobacter pylori infection by stool antigen testing\n* Willingness to comply with the assigned treatment regimen\n* Ability to provide informed consent\n* Willingness to complete follow-up evaluation\n\nExclusion Criteria:\n\n* Use of antibiotics within 4 weeks prior to enrollment\n* Active gastrointestinal infection other than Helicobacter pylori\n* Previous gastrointestinal tract surgery\n* Pregnant or lactating females\n* Known allergy or intolerance to study medications\n* Psychiatric illness or other condition impairing treatment compliance\n* Severe comorbid illness making participation unsuitable in the investigator's judgment",{"count":73,"type":21},90,[75],"NA","This randomized controlled trial aims to compare the efficacy and safety of levofloxacin-based sequential therapy versus bismuth-based quadruple therapy for eradication of Helicobacter pylori infection in adult patients. Helicobacter pylori infection remains highly prevalent in developing countries and is associated with gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, and gastric cancer. Increasing antibiotic resistance has reduced the effectiveness of conventional treatment regimens, creating a need for alternative first-line therapies with improved eradication rates and acceptable tolerability.\n\nEligible adult patients diagnosed with H. pylori infection by stool antigen testing will be recruited from the Gastroenterology Department of Services Hospital Lahore. Participants will be randomly assigned in a 1:1 ratio to receive either levofloxacin-based sequential therapy or bismuth-based quadruple therapy for 14 days.\n\nThe primary outcome of the study is successful eradication of H. pylori infection, confirmed by stool antigen testing performed 6 weeks after completion of therapy. Secondary outcomes include treatment-related adverse effects, treatment compliance, and overall treatment cost.\n\nThe study aims to identify an effective and affordable treatment strategy for H. pylori eradication in a population with high antibiotic resistance and socioeconomic limitations.",[27],"2026-05-02",{"date":57,"type":32},{"date":81,"type":21},"2026-06-01",{"date":83,"type":21},"2026-12-30",{"name":85,"class":64},"University of Health Sciences Lahore",{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100606715","efficacy-and-safety-of-14-day-vonoprazan-based-dual-therapy-versus-quadruple-therapy-for-helicobacter-pylori-eradication-a-multicentre-non-inferiority-randomized-controlled-trial-100606715","NCT07179159","Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 18-70 years, male or female\n2. Patients with H. pylori infection (positive 13C-urea breath test, together with at least one positive result from the following three tests: (a) stool H. pylori antigen test; (b) rapid urease test; (c) histopathological examination of gastric mucosal biopsy tissue)\n3. No prior Helicobacter pylori eradication therapy\n\nExclusion Criteria:\n\n1. Severe underlying conditions, such as hepatic insufficiency, renal insufficiency, malignant tumours\n2. Active gastrointestinal bleeding\n3. History of upper gastrointestinal surgery\n4. History of drug hypersensitivity\n5. Use of bismuth compounds or antibiotics within the past 4 weeks, or acid-suppressing agents within the past 2 weeks\n6. Pregnant or lactating women\n7. Presence of other risk-increasing behaviours such as alcohol abuse or illicit drug use\n8. Individuals unable or unwilling to provide informed consent","70 Years",{"count":94,"type":21},372,[75],"This study is a multicentre, non-inferiority randomized controlled trial to compare the efficacy and safety of 14-day vonoprazan-based dual therapy with versus quadruple therapy for the eradication of Helicobacter pylori. The primary outcome is eradication rate, and the secondary outcome includes the incidence of adverse events and compliance.",[27],"2026-04-14",{"date":100,"type":32},"2026-04-15",{"date":102,"type":32},"2025-09-09",{"date":104,"type":21},"2026-12-31",{"name":106,"class":64},"Yanqing Li",2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":4},"100633956","rescue-reatment-of-helicobacter-pylori-based-on-fecal-antimicrobial-resistance-gene-testing-100633956","NCT07533422","Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing","Multicenter, Randomized Controlled Study on Personalized Rescue Treatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing","Inclusion Criteria:\n\n* ① Age 18-70 years;\n\n  * Patients with Hp-positive chronic gastritis who have failed initial treatment, as confirmed by urea breath test or endoscopic biopsy;\n\n    * No use of PPIs, H2-receptor antagonists, antibiotics, or bismuth agents within 4 weeks;\n\n      * History of having received one previous, standardized Hp eradication therapy.\n\nExclusion Criteria:\n\n* ① Use of antibiotics, bismuth agents within 4 weeks prior to treatment, or use of PPIs or H₂-receptor antagonists within 2 weeks prior to treatment;\n\n  * History of gastric or duodenal surgery;\n\n    * Concurrent presence of other serious conditions such as cardiac, hepatic, or renal dysfunction, malignant tumors, or other severe internal diseases;\n\n      * Allergy to any component of the study medications; ⑤ Pregnant or breastfeeding women; ⑥ Participation in other drug studies within 3 months prior to treatment; ⑦ Patients unable to accurately express their complaints or cooperate with the study investigators.",{"count":116,"type":21},531,[75],"Helicobacter pylori(H. pylori, Hp) is a major etiological agent in chronic gastritis, peptic ulcer disease, gastric cancer, and gastric MALT lymphoma. Guideline recommend antimicrobial susceptibility testing following initial treatment failure to guide personalized therapy and improve eradication rates. However, conventional susceptibility testing faces two major limitations: 1) reliance on invasive endoscopic biopsy for tissue acquisition, and 2) dependency on bacterial culture, which is complex and time-consuming. Fecal-based antimicrobial resistance gene testing overcomes these barriers, offering distinct advantages of being non-invasive, rapid and accurate, thereby improving patient compliance. This study aims to elucidate the diagnostic value of fecal nucleic acid testing for H. pyloriinfection and to evaluate the eradication rate and safety of tailored triple therapy regimens selected based on fecal resistance gene profiles.",[27,120],"Rescue Therapy for Helicobacter Pylori","2026-04-09",{"date":123,"type":32},"2026-04-16",{"date":125,"type":21},"2026-05-12",{"date":127,"type":21},"2027-02-01",{"name":129,"class":64},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":40},"100616544","phase-4-eradication-of-helicobacter-pylori-improves-metabolic-syndrome-through-modulation-of-gut-microbiota-100616544","NCT07306988","Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.","Mechanisms of Gut Microbiota in Improving Metabolic Syndrome-Related Parameters Following Helicobacter Pylori Eradication","Inclusion Criteria:\n\n* For H. pylori-naïve infected patients with newly diagnosed metabolic syndrome (MS):\n\n  1. Aged 18-65 years;\n  2. Confirmed H. pylori-positive status by urea breath test (UBT), with no prior eradication therapy;\n  3. Newly diagnosed MS according to the Chinese Diabetes Society (CDS, 2004 Chinese criteria) ;\n  4. Voluntarily join the trial and sign informed consent.\n* For H. pylori-negative healthy controls with normal metabolism:\n\n  1. Aged 18-65 years;\n  2. Confirmed H. pylori-negative status by UBT;\n  3. Normal metabolic parameters (e.g., blood glucose, lipid profile, blood pressure) without MS;\n  4. Voluntarily join the trial and sign informed consent.\n\nExclusion Criteria:\n\n1. Hypersensitivity to study drugs (e.g., penicillin, amoxicillin, vonoprazan);\n2. Active peptic ulcer confirmed by endoscopy;\n3. Prior history of H. pylori eradication therapy;\n4. Use of medications for metabolic regulation (e.g., hypoglycemic agents, lipid-lowering drugs, weight-loss drugs)\n5. Recent use of antibiotics or bismuth (within 4 weeks) or H2-receptor antagonists\u002FPPIs (within 2 weeks) before enrollment;\n6. Current use of corticosteroids, NSAIDs, or anticoagulants;\n7. History of esophageal or gastric surgery;\n8. Pregnant or breastfeeding women;\n9. Severe comorbidities (e.g., hepatic, cardiovascular, pulmonary, renal diseases, inflammatory bowel disease);\n10. Chronic alcohol abuse (\\>40 g\u002Fday for men, \\>20 g\u002Fday for women);\n11. Malignancies (e.g., gastric mucosa-associated lymphoid tissue \\[MALT\\] lymphoma).",true,"65 Years",{"count":140,"type":21},120,[142],"PHASE4","The Role of Gut Microbiota in the Mechanism of Helicobacter pylori Eradication-Induced Amelioration of Metabolic Syndrome-Related Parameters\n\nStudy Sponsor: Nanjing First Hospital Principal Investigator: Dr. Wanli Liu Department: Gastroenterology Study Duration: February 2025 - August 2025\n\nKey Information for Patients and Families\n\n1. What is this study about? This study aims to understand how treating a common stomach infection caused by Helicobacter pylori (Hp) might improve metabolic health issues like high blood sugar, cholesterol problems, or obesity (collectively called metabolic syndrome). Specifically, it explores whether adding probiotics (good bacteria) or a natural compound called berberine (BBR) to standard Hp treatment can enhance these benefits by improving gut bacteria balance.\n2. Who can participate? Patients: Adults aged 18-65 with both Helicobacter pylori infection (confirmed by a breath test) and newly diagnosed metabolic syndrome (based on waist size, blood sugar, cholesterol, or blood pressure).\n\n   Healthy Volunteers: Adults aged 18-65 with no Hp infection and normal metabolic health (to compare results).\n\n   Exclusions:\n\n   Allergy to study medications (e.g., penicillin).\n\n   Previous Hp treatment, recent antibiotic\u002Fsteroid use, pregnancy, or serious medical conditions (e.g., liver\u002Fkidney disease).\n3. What will participants do?\n\n   Treatment Groups:\n\n   Group A: Take two medications (vonoprazan + amoxicillin) for 14 days.\n\n   Group B: Take the two medications + probiotics (Bifidobacterium tablets).\n\n   Group C: Take the two medications + berberine (a plant-based supplement).\n\n   Tests:\n\n   Before treatment: Breath test, blood tests (blood sugar, cholesterol, inflammation markers), stool sample analysis (gut bacteria), and body measurements (weight, waist size).\n\n   After treatment (1 month): Repeat tests to check Hp eradication and metabolic improvements.\n4. Possible Benefits and Risks\n\n   Benefits:\n\n   Free Hp treatment and metabolic health monitoring.\n\n   Potential improvement in blood sugar, cholesterol, or weight.\n\n   Contribution to future treatments for metabolic syndrome.\n\n   Risks:\n\n   Mild side effects (e.g., nausea, diarrhea, stomach pain) from medications.\n\n   Discomfort from blood draws or stool sample collection.\n5. How are participants protected? All treatments are FDA-approved or widely used in clinical practice.\n\nEthical review ensures participant safety.\n\nYou can withdraw at any time without affecting your regular care.\n\nInformation for Health Care Providers\n\n1. Study Design Type: Prospective, single-center, open-label, randomized controlled trial.\n\n   Population: 140 participants (120 Hp+ patients with metabolic syndrome; 20 Hp- healthy controls).\n\n   Intervention:\n\n   Group A: Vonoprazan (20 mg bid) + amoxicillin (1 g tid) for 14 days.\n\n   Group B: Group A + Bifidobacterium tetragenous probiotic (3 tablets tid).\n\n   Group C: Group A + berberine (3 tablets tid).\n\n   Primary Outcomes:\n\n   Hp eradication rate (confirmed by urea breath test).\n\n   Changes in metabolic parameters (fasting glucose, HbA1c, lipid profile).\n\n   Gut microbiota composition (16S rRNA sequencing).\n\n   Secondary Outcomes:\n\n   Multi-omics analysis (inflammation markers, endotoxins, short-chain fatty acids, bile acids).\n2. Scientific Rationale Hp and Metabolic Syndrome: Epidemiological evidence links Hp infection to metabolic dysfunction, possibly via chronic inflammation. Eradication may partially reverse insulin resistance and dyslipidemia.\n\n   Gut Microbiota as Mediator: Hp eradication alters gut microbiota, which regulates metabolic homeostasis through metabolites (e.g., SCFAs), bile acid metabolism, and inflammatory pathways. Probiotics\u002FBBR may enhance these effects.\n3. Methodology Randomization: Block randomization (block size = 4) using SAS 9.4.\n\n   Assessments:\n\n   Metabolic Parameters: Fasting glucose, HbA1c, lipid profile, BMI.\n\n   Microbiome: 16S rRNA sequencing (α\u002Fβ diversity, taxa abundance).\n\n   Multi-omics: ELISA (TNF-α, IL-6), GC-MS (SCFAs), UPLC-MS (bile acids).\n\n   Statistical Analysis:\n\n   Microbiome: QIIME2, LEfSe, PICRUSt2.\n\n   Multi-omics: limma, SparCC, sPLS-DA.\n\n   Clinical data: ANOVA, χ² tests (SPSS v25.0).\n4. Clinical Implications Clarify whether probiotics or BBR add value to Hp eradication in improving metabolic health.\n\nIdentify gut microbiota-driven mechanisms linking Hp eradication to metabolic benefits.\n\nResources for Participants\n\nStudy Flowchart:\n\nScreening: Breath test, blood\u002Fstool tests (1 week).\n\nTreatment: 14 days of medication.\n\nFollow-up: Repeat tests at 1 month.\n\nContact Information:\n\nDr. Wanli Liu: +86-18951670222\n\nNanjing First Hospital Gastroenterology Department.\n\nFAQ Sheet:\n\nCan I take my regular medications? Yes, unless they interfere with Hp treatment (e.g., PPIs).\n\nWhat if I miss a dose? Contact the study team immediately.\n\nEthical Compliance Approved by the Institutional Review Board of Nanjing First Hospital.\n\nComplies with the Declaration of Helsinki and China's ethical guidelines.\n\nInformed consent required for participation.",[27,145],"Metabolic Syndrome",{"date":147,"type":32},"2026-04-13",{"date":149,"type":32},"2025-04-17",{"date":151,"type":21},"2026-06-30",{"name":153,"class":64},"Nanjing First Hospital, Nanjing Medical University",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":164,"studyType":165,"phases":4,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":107},"100618729","registry-for-the-management-of-helicobacter-pylori-infection-in-shandong-province-100618729","NCT07335406","Registry for the Management of Helicobacter Pylori Infection in Shandong Province","Hp-SHAREReg","Inclusion Criteria:\n\n* patients aged 18-80 years, regardless of gender;\n* willing to receive H. pylori eradication therapy;\n* diagnosed with H. pylori infection through at least one of the following methods: rapid urease test, ¹³C\u002F¹⁴C-urea breath test, or histopathological examination.\n\nExclusion Criteria:\n\n* patients with incomplete medical records, including missing treatment details, absence of post-treatment follow-up test results, or failure to complete essential follow-up assessments;\n* patients with severe underlying conditions such as hepatic insufficiency, renal insufficiency, or malignant tumours;\n* pregnant or breastfeeding women;\n* individuals who refuse to sign the informed consent form","80 Years",{"count":163,"type":21},10000,"1 Year","OBSERVATIONAL","Helicobacter pylori infection is a common global gastrointestinal infectious disease, affecting approximately 43.1% of the world's population. Eradicating H. pylori is crucial for reducing the risk of developing conditions such as gastritis, peptic ulcer disease, and gastric cancer. Currently, 14-day high-dose dual therapy containing amoxicillin and bismuth-containing quadruple therapy are the guideline-recommended first-line treatment regimens for H. pylori eradication. Treatment options for H. pylori vary considerably, with differing efficacy outcomes largely attributable to increasing bacterial antibiotic resistance. Furthermore, multiple factors influence the efficacy of H. pylori eradication, including smoking, body surface area, CYP2C19 gene polymorphisms, patient compliance, and regional variations.\n\nTherefore, to systematically evaluate the efficacy and safety of different treatment regimens alongside the cost-effectiveness of various therapeutic strategies, and to conduct ongoing critical analysis of clinical practice, this study proposes a long-term investigation of real-world clinical practice through a non-interventional cohort study registry. This will assess the effectiveness, safety, and temporal trends of different H. pylori infection treatment regimens, providing real-time evidence to support clinical practice.",[27],[169],"Helicobacter pylori","2026-03-27",{"date":172,"type":32},"2026-04-02",{"date":174,"type":32},"2026-02-01",{"date":176,"type":21},"2035-11-30",{"name":178,"class":64},"Yueyue Li",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":137,"sex":16,"minAge":187,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":40},"100619584","endoscopic-screening-of-asymptomatic-patients-for-helicobacter-pylori-intestinal-metaplasia-and-barretts-mucosa-during-screening-colonoscopy-100619584","NCT07346521","Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy","Endoscopic Screening of Asymptomatic Patients for Helicobacter Pylori, Intestinal Metaplasia, and Barrett's Mucosa During Screening Colonoscopy - a Cross-sectional Study","G-SCOGE","Inclusion Criteria:\n\n* Age ≥ 30 years\n* Scheduled screening colonoscopy (either initial screening or surveillance following previously detected polyps)\n* Asymptomatic (no gastrointestinal symptoms)\n* Willingness and consent to undergo simultaneous gastroscopy with biopsy sampling\n* Written informed consent to participate in the study, including the use of histological findings and patient data for study analysis\n\nExclusion Criteria:\n\n* Known Helicobacter pylori infection or previous treatment for H. pylori\n* Current or recent proton pump inhibitor (PPI) therapy (\\\u003C 4 weeks)\n* Pre-existing gastrointestinal diseases (e.g., chronic gastritis, ulcer, gastric carcinoma)\n* Immunosuppression or relevant underlying diseases\n* Refusal to undergo additional gastroscopy or biopsy","30 Years",{"count":189,"type":21},1000,"The goal of this observational study is to learn how common Helicobacter pylori (H. pylori) infection is in adults without stomach or upper gastrointestinal symptoms who are having a preventive screening colonoscopy.\n\nEndoscopic screening of the stomach is yet not acceptet as a standard screening procedure in Western countries. However, Helicobacter pylori infection is known to increase the risk of developing gastric cancer.\n\nThis study will look at the prevalence of Helicobacter pylori infection in asymptomatic patients who have an additional gastroscopy during the same session as their screening colonoscopy. It will also record other early tissue changes or risk factors for stomach cancer, such as intestinal metaplasia and Barrett's mucosa.\n\nThe main questions this study aims to answer are:\n\n* How often is Helicobacter pylori found in adults without upper gastrointestinal symptoms by use of OGD?\n* Are there any correlations between H. pylori infection and other risk factors, such as BMI, smoking, alcohol consumption, or a family history of colorectal and\u002For stomach cancer?\n\nAbout 1000 participants are expected to take part. Adults undergoing a screening colonoscopy at a private endoscopy center will be offered the chance to have an additional gastroscopy if they meet the study's inclusion criteria (no previous Helicobacter pylori infection and no upper gastrointestinal symptoms).\n\nSmall tissue samples (biopsies) will be taken from the stomach and lower esophagus during the gastroscopy. Biopsies will be checked histologically for the presence of Helicobacter pylori and early tissue changes.\n\nDuring the gastroscopy, no additional procedures or biopsies will be done beyond what is normally performed during a routine examination. Everything done during this procedure follows the standard steps of a regular gastroscopy.\n\nAll data will be coded to protect participant privacy. Researchers will use statistical methods to find out how common Helicobacter pylori infection is and whether it is related to other lifestyle or family risk factors or tissue changes.",[27,192,193],"Intestinal Metaplasia","Barett's Esophagus","2026-03-05",{"date":196,"type":32},"2026-03-09",{"date":198,"type":32},"2025-12-16",{"date":200,"type":21},"2026-12-16",{"name":202,"class":64},"Sigmund Freud PrivatUniversitat",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":212,"conditions":213,"keywords":218,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":4},"100628196","predicting-peptic-complications-using-h-pylori-serology-and-gastric-ultrasound-100628196","NCT07458490","Predicting Peptic Complications Using H. Pylori Serology and Gastric Ultrasound","H. Pylori Serology and Gastric Ultrasound Findings in Predicting Peptic Complications","Inclusion Criteria:\n\n* Adult patients (age ≥18 years) presenting with dyspeptic symptoms (epigastric pain, nausea, vomiting, heartburn).\n* Patients with suspected or confirmed peptic ulcer disease.\n* Patients presenting with acute complications (hematemesis, melena, acute - abdominal pain suggestive of perforation).\n* Patients with history of peptic ulcer disease requiring surveillance.\n* Patients who provide informed consent.\n\nExclusion Criteria:\n\n* Previous gastric surgery (gastrectomy, vagotomy).\n* Active malignancy (gastric cancer, lymphoma).\n* Previous H. pylori eradication therapy within 4 weeks.\n* Current use of proton pump inhibitors (PPIs) within 2 weeks (may affect antibody levels and ultrasound findings).\n* Severe coagulopathy or bleeding disorders (INR \\>2.0).\n* Pregnancy.\n* Poor quality ultrasound images due to excessive bowel gas or obesity.\n* Hemodynamically unstable patients requiring immediate intervention.\n* Refusal to participate in the study.",{"count":211,"type":21},230,"This observational study aims to evaluate whether combining a simple blood test (H. pylori serology) with a non-invasive abdominal ultrasound can accurately predict severe complications in patients with peptic ulcer disease (PUD). Peptic ulcer complications, such as stomach bleeding or perforation, are serious and typically require an invasive procedure called an upper endoscopy for diagnosis and treatment.\n\nResearchers want to find out if these two non-invasive tests can be used together to create a reliable risk-scoring system. This system would help doctors quickly identify which patients are at a high risk for complications and need an urgent endoscopy, compared to those who are at a lower risk and can be safely monitored without the invasive procedure.\n\nThe study will include adult patients presenting with stomach symptoms (like pain, nausea, or heartburn), as well as those with suspected or confirmed peptic ulcer disease. Participants will provide a blood sample to check for H. pylori antibodies and undergo a standard, painless abdominal ultrasound to examine the thickness of their stomach wall. An upper gastrointestinal endoscopy will be performed if it is clinically necessary as part of the patient's standard medical care.",[214,27,215,216,217],"Peptic Ulcer Disease","Helicobacter Pylori Infection","Peptic Ulcer","Dyspepsia",[219,220,221,214,215,222,217],"H. pylori serology","gastric ultrasound","peptic complications","Peptic Ulcer Complications","2026-03-04",{"date":196,"type":32},{"date":226,"type":21},"2026-04",{"date":228,"type":21},"2027-05",{"name":230,"class":64},"Assiut University",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":40},"100615538","phase-2-vonoprazan-vs-proton-pump-inhibitor-with-vitamin-d-or-probiotics-based-triple-therapy-for-eradication-of-helicobacter-pylori-infection-100615538","NCT07293910","Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","Safety and Efficacy of Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection","Inclusion Criteria:\n\n* Both male and female patients. • Patients ≥ 18 and \\\u003C80 years old.\n\nPatients with confirmed diagnosis of H. pylori infection using either stool antigen test, urea breath test or endoscopy.\n\nExclusion Criteria:\n\n* Pregnant or lactating patients. • Patients with inflammatory diseases. • Patients sensitive to any of the regimens' components. • Patients who had received a previous eradication therapy, recent use of antimicrobial agents, proton pump inhibitors, and H2 receptor blockers within 1 month.\n\nPatients with previous incidents of gastric or duodenal bleeding, gastric surgery or gastric malignancy.\n\n• Patients with active liver disease.\n\n• Patients with renal impairment.\n\n• Concurrent use of liver enzyme inducers, inhibitors or drugs with high plasma protein binding.",{"count":239,"type":21},66,[241],"PHASE2","Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that infects up to 50% of the world's population, residing in the gastric mucosa and using the mucus layer for protection from the stomach's high acidity. Its clinical significance is profound: it is classified as a Group 1 carcinogen by the World Health Organization and is a primary cause of chronic gastritis, peptic ulcers, gastric lymphoma, and gastric carcinoma. The current first-line treatment, a PPI-based triple therapy (PPI + clarithromycin + amoxicillin), is experiencing a decline in efficacy (cure rates of 50-70%) due to widespread antibiotic resistance and compliance issues. To overcome this, newer agents like Vonoprazan Fumarate, a Potassium-Competitive Acid Blocker (P-CAB), are being adopted. Vonoprazan works by reversibly inhibiting the H+, K+ ATPase pump achieving stronger and longer-lasting acid suppression than PPIs because it does not require acid activation and is more stable in an acidic environment. In addition to pharmacological treatment, adjunctive therapies show promise. Vitamin D, acting through Vitamin D Receptor (VDR), assists in eradication by upregulating antimicrobial proteins like beta-defensin and cathelicidin, and its metabolite can cause bacterial cell lysis. Probiotics (primarily Lactobacillus and Bifidobacterium strains) enhance eradication rates by restricting bacterial growth, inhibiting adhesion, and exerting an anti-inflammatory effect through decreased interleukin-8 production. Finally, helicobacter pylori infection is marked by significant inflammation and oxidative stress. The bacterial protein TIP alpha induces high levels of the pro-inflammatory cytokine TNF alpha. Furthermore, the infection increases free radical production, leading to oxidative stress reflected by high levels of malondialdehyde. Systemic inflammation is also evident as helicobacter pylori infection is associated with significantly elevated serum C-reactive protein levels, which decrease upon successful eradication.\n\nAim of the work:\n\nThis study aims at evaluating the safety and efficacy of Vonoprazan vs Proton Pump Inhibitor with Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection.",[27,244,245,246],"Helicobacter Infection","Helicobacter Pylori Gastrointestinal Tract Infection","Helicobacter Pylori Infected Patients",[248,249,250,251,252,253,254,255],"Helicobacter Pylori","Vonoprazan","Vitamin D","Probiotics","Lactobacillus","C-reactive protein","Tumor necrosis factor alpha","Malondialdehyde","2026-02-11",{"date":258,"type":32},"2026-02-13",{"date":260,"type":21},"2026-02-15",{"date":262,"type":21},"2026-12-20",{"name":264,"class":64},"Tanta University",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100624134","phase-4-fecal-molecular-susceptibility-guided-hp-first-line-therapy-100624134","NCT07405684","Fecal Molecular Susceptibility-guided Hp First-line Therapy","Clinical Efficacy and Health Economic Evaluation of Fecal Molecular Susceptibility-guided Therapy for Helicobacter Pylori Infection First-line Treatment: Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n1. Voluntarily participate in this clinical study; fully understand, be informed about this study, and sign the Informed Consent Form (ICF).\n2. Age between 18 and 75 years (inclusive) on the day of signing the ICF.\n3. 13C-urea breath test (13C-UBT) and fecal HP nucleic acid detection confirming Helicobacter pylori (Hp) infection.\n4. Not previously eradicated HP\n\nExclusion Criteria:\n\n1. Individuals with a known allergy to the medication.\n2. Patients with severe cardiovascular, pulmonary, renal, hepatic, hematologic, neurologic, endocrine, or psychiatric disorders;\n3. Participants or guardians who refuse to enroll;\n4. Alcohol and\u002For drug abuse (dependence or addiction) or individuals judged by the physician to have poor compliance; 5) Use of antibiotics, bismuth-containing drugs, PPIs, or traditional Chinese medicines within 4 weeks before treatment; 6) Pregnant or lactating women; 7) Any condition deemed by the investigator to be unsuitable for enrollment.",{"count":273,"type":21},544,[142],"The goal of this clinical trial is to evaluate the eradication efficacy and health economic benefits of individualized regimens guided by fecal molecular susceptibility testing with 7-day and 14-day courses in the first-line treatment of Helicobacter pylori infection. The main questions it aims to answer are:\n\n1. What is the H. pylori eradication rate of the 7-day versus 14-day individualized regimens?\n2. What are the safety, adherence, and cost-effectiveness of the 7-day versus 14-day individualized regimens? Researchers will compare the 7-day course group and the 14-day course group to see if the 7-day course is non-inferior to the 14-day course in terms of eradication rate.\n\nParticipants will:\n\n1. Undergo fecal H. pylori drug resistance gene testing\n2. Receive randomized assignment to either 7-day or 14-day individualized treatment based on drug susceptibility results\n3. Complete follow-up visits at 1 week and 4-8 weeks after stopping treatment for adverse event monitoring and 13C-urea breath test",[27],[169],"2026-02-10",{"date":280,"type":32},"2026-02-12",{"date":282,"type":21},"2026-02-28",{"date":284,"type":21},"2028-12-31",{"name":286,"class":64},"Shanghai Zhongshan Hospital",4,{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":137,"sex":16,"minAge":164,"maxAge":17,"enrollmentInfo":296,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":301,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":40},"100616067","mirna-in-pediatric-gastritis-100616067","NCT07300787","miRNA in Pediatric Gastritis","Role of miRNA-155 and miRNA-204 in Pediatric Gastritis","microRNA","Inclusion Criteria:\n\nrecurrent abdominal pain warranting upper gastrointestinal endoscopy or gastroscopy including\n\n* peptic-like dyspepsia (identified by two or more symptoms such as periodic pain, pain relief with food or antacid, pre-meal or hunger-induced pain, nausea\u002Fvomiting, and nighttime pain),\n* dysmotility-like dyspepsia (characterized by abdominal distension, anorexia, weight loss, pain worsening with food\u002Fmilk, and belching),\n* and reflux-like dyspepsia (manifesting as heartburn, chest pain\n\nexclusion criteria:\n\n-patients with gastrointestinal disorders explaining abdominal pain (e.g., inflammatory bowel disease, celiac disease, functional abdominal pain)\n\n, -patients on proton pump inhibitors, as well as those with significant medical comorbidities.\n\nExclusion Criteria:\n\n\\-",{"count":297,"type":21},100,[75],"The goal of this clinical trial is to assess the differential expression of miR-155 and miRNA-204 in relation to gastritis, and assess their relation with the presence of H. pylori in children.",[27],[302,303,304,305],"miRNA-155","miRNA-204","gastritis","H.pylori","2025-12-18",{"date":308,"type":32},"2025-12-24",{"date":310,"type":21},"2026-01-20",{"date":81,"type":21},{"name":313,"class":64},"Benha University",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":320,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":326,"startDateStruct":327,"completionDateStruct":328,"leadSponsor":330,"locationsCount":40},"100614148","phase-3-comparative-study-evaluating-safety-and-effectiveness-of--proton-pump-inhibitor-versus-vonoprazan--based-triple-therapy-with-or-without-zinc-to-eradicate-h-pylori-infection-100614148","NCT07275827","Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection","Inclusion Criteria:\n\n* Age \\> 18.\n* Both males and females.\n* Patients who are positive for H.pylori infection by non-invasive Stool Antigen Test (SAT).\n\nExclusion Criteria:\n\n* Prior H. pylori treatment: Previous treatment for H. pylori infection.\n* Allergies: Known allergies to study medications or components.\n* Patients cannot finish treatment course.\n* Pregnant and Lactating Women.\n* Patients with Kidney disease and eGFR \\\u003C 30ml\u002Fmin.\n* Patients with Liver disease with Child-Pugh B or C.","19 Years",{"count":322,"type":21},88,[24],"this Study Evaluating Safety and Effectiveness of (Proton Pump Inhibitor versus Vonoprazan) Based Triple Therapy with or without Zinc to Eradicate H. pylori Infection",[27],{"date":308,"type":32},{"date":174,"type":21},{"date":329,"type":21},"2026-10",{"name":264,"class":64},{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":339,"conditions":340,"keywords":342,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":40},"100615426","prevalence-of-helicobacter-pylori-on-patients-with-chronic-inflammatory-bowel-disease-ibd-at-the-chu-of-guadeloupe-100615426","NCT07292454","Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe","HP-MICI","Inclusion Criteria:\n\nPatients over 18 years old Patients with IBD from the CHU of Guadeloupe Patients benefiting from an investigation of H. pylori infection through gastric biopsies and\u002For serology at the time of diagnosis of IBD Patients affiliated to the French social security system Free informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research)\n\nExclusion Criteria:\n\nPatients of less than18 years Patients having not given their writing informed consent",{"count":297,"type":21},"Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD). However, to the best of our knowledge, the composition of gastric and of intestinal microbiome has never been investigated in a population with IBD according to the presence\u002Fabsence of Helicobacter pylori (H. pylori) in the stomach.",[27,341],"Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)",[343,344,27,345],"intestinal microbioma","gastric microbioma","Inflammatory Bowel Disease","2025-12-05",{"date":306,"type":32},{"date":349,"type":21},"2025-12-15",{"date":351,"type":21},"2026-12-15",{"name":353,"class":64},"Centre Hospitalier Universitaire de la Guadeloupe",{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":362,"targetDuration":4,"studyType":22,"phases":364,"briefSummary":365,"conditions":366,"keywords":367,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":384,"locationsCount":40},"100611581","phase-4-tegoprazan-plus-amoxicillin-bid-vs-tid-regimens-for-h-pylori-eradicationfrequency-adjusted-same-dose-therapy-for-h-pylori-100611581","NCT07242443","Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）","A Randomized Controlled Trial Comparing Tegoprazan 50 mg BID Combined With Amoxicillin 1 g TID Versus Tegoprazan 50 mg BID Combined With Amoxicillin 1.5 g BID for the Eradication of Helicobacter Pylori","FAST-HP","Inclusion Criteria:\n\n\\- 1.Adults aged 18 to 70 years. 2.Confirmed Helicobacter pylori infection by ¹³C-urea breath test, stool antigen test, or gastric biopsy.\n\n3.Able to provide written informed consent. 4.Willing and able to comply with all study procedures, including follow-up testing 4-8 weeks after treatment.\n\nExclusion Criteria:\n\n* 1.Known allergy or hypersensitivity to tegoprazan, amoxicillin, or any β-lactam antibiotics.\n\n  2.Use of antibiotics, proton pump inhibitors (PPIs), bismuth-containing agents, or potassium-competitive acid blockers within 4 weeks before screening.\n\n  3.Severe hepatic impairment (ALT or AST \\> 3 × upper limit of normal). 4.Severe renal impairment (estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n\n  5.Pregnant or breastfeeding women. 6.History of gastric surgery or conditions that may affect gastrointestinal absorption.\n\n  7.Participation in another clinical trial within the past 30 days. 8.Any condition that, in the investigator's judgment, would make the participant unsuitable for the study.",{"count":363,"type":21},240,[142],"This study is designed to evaluate two different tegoprazan-based dual therapy regimens for the treatment of Helicobacter pylori (H. pylori) infection. All participants will receive tegoprazan 50 mg twice daily for 14 days, combined with one of two amoxicillin dosing schedules that contain the same total daily dose of 3 grams of amoxicillin.\n\nOne group will receive amoxicillin 1 gram three times daily (TID), which is the standard regimen. The other group will receive amoxicillin 1.5 grams twice daily (BID), an alternative schedule that may improve convenience and treatment adherence while maintaining the same total daily antibiotic amount.\n\nA total of 240 adults with confirmed H. pylori infection will be randomly assigned to one of the two treatment groups. The main goal of the study is to compare the H. pylori eradication rates between the two regimens. Eradication will be assessed 4 to 8 weeks after completing therapy using a ¹³C-urea breath test. Safety, tolerability, and medication adherence will also be monitored.",[27],[169,368,369,370,371,372,373,374,375,376,377],"H. pylori","Amoxicillin","Tegoprazan","Dual Therapy","BID Dosing","TID Dosing","Fixed-Dose Regimen","P-CAB","Frequency Comparison","Antibiotic Regimen Optimization","2025-11-17",{"date":380,"type":32},"2025-11-21",{"date":382,"type":21},"2025-11-20",{"date":104,"type":21},{"name":385,"class":64},"First People's Hospital of Hangzhou",{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":394,"enrollmentInfo":395,"targetDuration":397,"studyType":165,"phases":4,"briefSummary":398,"conditions":399,"keywords":400,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":40},"100599385","feasibility-study-to-diagnose-helicobacter-pylori-in-the-paediatric-population-using-non-invasive-fecal-analysis-100599385","NCT07083804","Feasibility Study to Diagnose Helicobacter Pylori in the Paediatric Population Using Non-invasive Fecal Analysis","Feasibility Study to Diagnose Helicobacter Pylori In The Paediatric Population Using Non-Invasive Fecal Analysis: the HEPYCA Study","HEPYCA","Inclusion Criteria:\n\n* Age \\\u003C or = 16 years ;\n* Any indication for gastroscopy in children requiring gastric biopsies: gastro-esophageal reflux resistant to proton pump inhibitors (PPIs) or recurrent on discontinuation of PPIs, hematemesis, refractory anemia or unexplained inflammatory syndrome, recurrent vomiting, dysphagia, endoscopic assessment of chronic inflammatory bowel disease with search for H. pylori superinfection ;\n* Patients benefiting from a Social Security scheme or benefiting from one via a third part;\n* Holders of parental authority who have given their informed consent to participate in the study and child participants of understanding age who have given their assent.\n\nNon-inclusion Criteria:\n\n* Antibiotic treatment less than 4 weeks\n* PPIs treatment less than 2 weeks\n* Contraindication to endoscopic procedure or biopsy.\n\nExclusion Criteria:\n\n* Antibiotic therapy prior to stool collection (between inclusion and stool collection, which may be 10 days later)\n* Failure to send\u002Freceive stool sample\n* Biopsy not performed at endoscopy","16 Years",{"count":396,"type":21},188,"10 Days","Helicobacter pylori infection is a widespread bacterial disease affecting nearly half of the world's population. In children, the infection displays distinct features versus adults, with lower prevalence, variable symptoms, and differing endoscopic and histological appearances.\n\nTypically acquired in early childhood, its transmission is closely linked to socio-economic disadvantage and overcrowding. Although most infected children are asymptomatic, some develop epigastric pain, dyspepsia, weight loss, or other gastrointestinal disturbances. Chronic infection may eventually lead to mucosal atrophy and intestinal metaplasia, increasing the risk of gastric cancer later in life. Given the limitations and risks of invasive diagnostic methods-especially endoscopy under general anesthesia-there is a critical need for reliable, non-invasive tests. Recent adult studies indicate that stool-based PCR is a promising alternative for both detecting H. pylori and identifying clarithromycin resistance.\n\nThe primary objectives of this study are to evaluate the intrinsic diagnostic performance of high-resolution melt PCR (HP PCR) in stools, and to compare these results with those obtained from a conventional work-up, such as gastric biopsies, in a paediatric population. In accordance with prevailing rationality, the principal outcome of this study will be an evaluation of the intrinsic diagnostic capabilities of the proposed method. This will be accomplished by conducting a comparison of the sensitivity and specificity of the PCR test in stools with those of gastric biopsies (reference test).",[27],[401,402,403,404,169],"Pediatrics","Gastroenterology","Microbiology","Infectious disease",{"date":382,"type":32},{"date":407,"type":32},"2025-10-07",{"date":409,"type":21},"2028-03",{"name":411,"class":64},"Poitiers University Hospital",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":40},"100602956","efficacy-of-vonoprazan-based-rescue-therapy-for-h-pylori-eradication-100602956","NCT07130253","Efficacy of Vonoprazan-based Rescue Therapy for H. Pylori Eradication","Inclusion Criteria:\n\n1. Helicobacter pylori infected individuals who have failed at least two previous eradication therapies.\n2. Willing to undergo third-line eradication therapy.\n3. Subjects must be 20 years of age or older.\n\nExclusion Criteria:\n\n1. History of gastrectomy.\n2. Individuals unsuitable for the study medication, such as those with a history of allergy or severe adverse reactions to the study drugs, quinolone or fluoroquinolone antibiotics, or women who are pregnant or breastfeeding.\n3. Presence of severe acute or chronic diseases such as renal failure, liver cirrhosis, incurable malignant tumors, or a history of aortic aneurysm or dissection.\n4. Patients with chronic hepatitis (AST or ALT \\> 100 U\u002FL).\n5. Unwillingness to comply with the treatment plan or sign the informed consent form.",{"count":419,"type":21},220,[75],"1. This study aims to compare the efficacy of empirical vonoprazan-based therapy versus susceptibility-guided vonoprazan-based therapy for third-line eradication of H. pylori.\n2. We also plan to explore the impact of eradication therapy on gut microbiota, fecal antibiotic resistance, and metabolic parameters before and after treatment.",[27],"2025-08-12",{"date":425,"type":32},"2025-08-19",{"date":427,"type":21},"2025-08-18",{"date":429,"type":21},"2030-06-30",{"name":63,"class":64},{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":137,"sex":16,"minAge":438,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":448,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":40},"100212860","phase-4-multicentric-randomized-study-of-h-pylori-eradication-and-pepsinogen-testing-for-prevention-of-gastric-cancer-mortality-100212860","NCT02047994","Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality","GISTAR","Inclusion Criteria:\n\n* Men and women aged 40-64 at the time of signing the consent form\n* Willingness to get involved in the study irrespective in which of the study arms (after detailed information on the potential benefits and risks that this study may confer)\n* The person has signed a consent form (including the acceptance of transporting the samples over the borders, as appropriate)\n* To be in good health, as determined by a physical examination and history performed by a study physician at enrolment\n\nExclusion Criteria:\n\n* Personal history of gastric cancer (prevalent gastric cancer cases will not be revealed at the time of inclusion, and therefore will be included)\n* Gastric resections due to benign disease (ulcer suturing and vagotomy are accepted)\n* H. pylori eradication therapy within 12 months prior to inclusion (irrespective of the treatment result)\n* Presence of alarm symptoms for digestive or any other diseases (detailed in the questionnaire or during the physician evaluation)\n* Pathological findings at physical investigation suggestive for a serious organic disease (physician evaluation)\n* Serious co-morbid condition with life expectancy less than 5 years (physician evaluation)\n* Factors otherwise limiting the participation according to the protocol conditions (problems of mobility, etc.)\n* Serious psychological conditions\u002Fpsychiatric disease limiting the possibilities to understand the requirements for diagnostic and\u002For medical interventions (physician evaluation)\n* Low expectations on the compliance for the diagnostic work-up or treatment (physician evaluation)\n* Expected loss for the follow-up (e.g. lack of communication possibilities and data entry in the registries, expected travel abroad, etc.) (physician evaluation)\n* Signed consent form is not available","40 Years","64 Years",{"count":441,"type":21},30000,[142],"Currently no ideal preventive modalities are available for reducing gastric-cancer caused mortality in organized population-based application. The primary objective of the study is to determine if H.pylori screening followed by eradication of positive subjects and endoscopic follow-up of those with serological evidence of atrophic gastritis reduces mortality from gastric cancer in middle-aged people in high-risk areas. The GISTAR study is a multicenter randomized study of H.pylori eradication and pepsinogen testing for prevention of gastric cancer mortality. Altogether 30.000 individuals aged 40-64 years will be enrolled, providing 90% study power to detect at least 35% reduction in gastric cancer mortality at 15 years of follow-up. Participants will be randomly allocated to one of two groups. In the active investigation\u002Fmanagement group those positive for H.pylori will be offered eradication therapy and individuals with decreased pepsinogen I\u002FII ratio will be invited for endoscopy. The control group will receive standard health care. The primary endpoint for this trial will be the mortality difference from gastric cancer between the two groups at 15 years or when enough cases accumulate to demonstrate a statistical difference. The study is expected to provide valuable information on the utility for reduction in gastric cancer mortality of: 1) H.pylori eradication in adults on a population-basis, including subjects who may already have pre-malignant lesions; and 2) pepsinogen testing in screening settings. A pilot study of 3,455 individuals prior to the main trial was conducted from October 2013 to December 2016.",[445,446,447],"Helicobacter Pylori Infections","Atrophic Gastritis","Gastric Cancer",[449,450,451,452,453,454],"Gastric cancer","Gastric cancer mortality","Helicobacter pylori treatment","Pepsinogen testing","Endoscopy","Volatile marker","2025-04-30",{"date":457,"type":32},"2025-05-02",{"date":459,"type":32},"2013-03",{"date":461,"type":21},"2035-12",{"name":463,"class":64},"International Agency for Research on Cancer",{"id":465,"slug":466,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":16,"minAge":471,"maxAge":472,"enrollmentInfo":473,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":4},"100588179","effect-of-hpylori-infection-on-growth-parameters-100588179","NCT06938035","Effect of H.Pylori Infection on Growth Parameters","Effect of H.Pylori Infection on Growth Parameters Of Primary School-aged Children Attending Assuit University Children Hospital","Inclusion Criteria:\n\n1. Primary school children aged 6 to 12 years old.\n2. Children who have tested positive for Helicobacter pylori.\n\nExclusion Criteria:\n\n1. Children with primary malnutrition due to nutritional deficiency .\n2. Children with chronic illness","6 Years","12 Years",{"count":474,"type":21},75,"This study aimed to assess the effect H.pylori infection on growth parameter Of primary school-aged children Attending Assuit university chilren hospital",[27],"2025-04-21",{"date":479,"type":32},"2025-04-22",{"date":481,"type":21},"2025-05-13",{"date":483,"type":21},"2026-03-31",{"name":230,"class":64},{"id":486,"slug":487,"hasResults":11,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":492,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":4},"100583837","low-dose-amoxicillin-dual-therapy-combined-with-licorice-and-lotus-root-powder-helicobacter-pylori-treatment-100583837","NCT06881524","Low-Dose Amoxicillin Dual-Therapy Combined with Licorice and Lotus Root Powder Helicobacter Pylori Treatment","A Randomized Controlled Trial of Low-Dose Amoxicillin Dual-Therapy Combined with Licorice and Lotus Root Powder for the Treatment of Helicobacter Pylori Infection","Inclusion Criteria:\n\nAge 18-70 years, regardless of sex; Positive for Helicobacter pylori (Hp); No use of proton pump inhibitors (PPIs), H2-receptor antagonists, antibiotics, or bismuth compounds within the past 4 weeks;\n\nExclusion Criteria:\n\nA history of gastric or duodenal surgery; Presence of other severe comorbidities, including significant cardiac, hepatic, or renal dysfunction, malignancies, or other serious medical conditions; Allergy to any component of the investigational drug; Pregnant or breastfeeding women; Participation in another drug study within 3 months prior to enrollment in this study; Inability of the patient to accurately describe their symptoms or to comply with the requirements of this study.",{"count":493,"type":21},374,[75],"In recent years, the increasing prevalence of Helicobacter pylori (H. pylori, Hp) resistance has led to a gradual decline in the eradication rate of Hp. The growing resistance to antibiotics, particularly clarithromycin, has severely impacted the efficacy of Hp eradication. Dual-therapy regimen consisting of a proton pump inhibitor (PPI) and amoxicillin can overcome clarithromycin resistance in Hp and is effective for Hp treatment. Vonoprazan, a novel potassium-competitive acid blocker (P-CAB), has a stronger and more sustained inhibitory effect on gastric acid secretion compared to traditional PPIs. Dual-therapy regimens combining P-CABs and high-dose amoxicillin have demonstrated high eradication rates. However, the adverse effects associated with high-dose amoxicillin, such as nephrotoxicity, limit the application of this regimen. Our recent in vitro bacterial experiments and animal studies have shown that licorice, a traditional Chinese herbal medicine that is also used as a food, can inhibit the growth of Hp. This study is designed to compare a licorice-containing treatment regimen with a low-dose amoxicillin dual-therapy regimen in a clinical RCT to explore the efficacy of the former in Hp infection treatment.",[27],"2025-03-12",{"date":499,"type":32},"2025-03-18",{"date":501,"type":21},"2025-04-01",{"date":503,"type":21},"2025-08-01",{"name":129,"class":64},{"id":506,"slug":507,"hasResults":11,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":11,"sex":512,"minAge":17,"maxAge":513,"enrollmentInfo":514,"targetDuration":515,"studyType":165,"phases":4,"briefSummary":516,"conditions":517,"keywords":519,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":522,"lastUpdatePostDateStruct":523,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":528,"locationsCount":4},"100583011","impact-of-helicobacter-pylori-infection-on-prolactin-levels-in-reproductive-age-women-to-determine-whether-h-pylori-infection-is-associated-with-elevated-prolactin-levels-and-assess-the-clinical-implications-100583011","NCT06870773","Impact of Helicobacter Pylori Infection on Prolactin Levels in Reproductive-Age Women to Determine Whether H. Pylori Infection is Associated with Elevated Prolactin Levels and Assess the Clinical Implications","Impact of Helicobacter Pylori Infection on Prolactin Levels in Reproductive-Age Women in Upper Egypt","Inclusion Criteria:\n\n\\- 1. Age Range: Women aged 18 to 45 years. 2. Diagnosis of H. pylori Infection: Participants must have a confirmed diagnosis of H. pylori infection through non-invasive methods such as stool antigen tests or breath tests and IgM serum.\n\n3\\. Reproductive Age: Women must be within reproductive age and not currently pregnant or breastfeeding\n\nExclusion Criteria:\n\n* 1\\. Recent Antibiotic Use: Individuals who have taken antibiotics within the last month will be excluded to avoid interference with H. pylori detection.\n\n  2\\. Use of Proton Pump Inhibitors (PPIs): Patients using PPIs or other medications that affect gastric acid secretion within the last month will be excluded.\n\n  3\\. Endocrine Disorders: Women with known endocrine disorders such as hyperprolactinemia from other causes will be excluded.\n\n  4\\. Chronic Illnesses: Individuals with chronic illnesses that could affect prolactin levels (e.g., renal failure, liver disease) will also be excluded.","FEMALE","48 Years",{"count":474,"type":21},"1 Month","The research is a cross-sectional observational study conducted at Assiut University Hospital. It will involve 75 women aged 18-45 with confirmed H. pylori infection. The study will measure serum prolactin levels and H. pylori infection status through stool antigen tests. The primary outcome is comparing prolactin levels between H. pylori-positive and negative women. Secondary outcomes include analyzing correlations with clinical symptoms and demographic factors.",[27,518],"Hyperprolactinaemia",[305,520,521],"prolactin level","hyperprolactinemia","2025-03-06",{"date":524,"type":32},"2025-03-11",{"date":526,"type":21},"2025-06-01",{"date":83,"type":21},{"name":230,"class":64},{"id":530,"slug":531,"hasResults":11,"nctId":532,"briefTitle":533,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":535,"targetDuration":4,"studyType":165,"phases":4,"briefSummary":537,"conditions":538,"keywords":539,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":548,"locationsCount":40},"100572265","efficacy-of-a-14-day-bismuth-containing-quadruple-therapy-guided-by-drug-susceptibility-testing-in-patients-with-extremely-refractory-helicobacter-pylori-infection-an-exploratory-study-100572265","NCT06731023","Efficacy of a 14-Day Bismuth-Containing Quadruple Therapy Guided by Drug Susceptibility Testing in Patients with Extremely Refractory Helicobacter Pylori Infection: an Exploratory Study","Inclusion Criteria:\n\n1. Patients aged 18-65.\n2. Patients with H.pylori infection (Positive for rapid urease test or 13C urea breath test).\n3. Received at least two previous standard treatment protocols for Helicobacter pylori, and the application regimens included at least three low-resistance antibiotics.\n\nExclusion Criteria:\n\n1. Patients with serious underlying diseases, such as liver insufficiency, renal insufficiency, immunosuppression, malignant tumors, Coronary heart disease or coronary artery stenosis ≥75%.\n2. Patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial.\n3. Patients with active gastrointestinal bleeding.\n4. Patients with a history of upper gastrointestinal surgery.\n5. Patients allergic to treatment drugs.\n6. Patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks\n7. Patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse\n8. Patients who are unwilling or incapable to provide informed consents.",{"count":536,"type":21},30,"Helicobacter pylori (H. pylori) infection, a prevalent global infectious disease, is a significant contributor to gastric cancer and other morbidities, imposing a substantial disease burden. With the rise in antibiotic resistance, the eradication of H. pylori is encountering formidable challenges. A subset of individuals, despite undergoing multiple treatment regimens, remain unable to successfully eradicate the infection. The persistence of infection in these cases could be attributed to either the limitations of detection methods leading to false positives or to the infection by superbugs that are highly resistant to antibiotics. This study is designed to ascertain whether these patients are infected with superbugs by employing various diagnostic techniques. Additionally, it aims to assess the antibiotic resistance profiles of strains associated with extremely refractory H. pylori infections through drug susceptibility testing. Based on the identified sensitivities, the study seeks to tailor treatment protocols with bismuth-containing quadruple therapy (Containing two kinds of antibiotics: sensitive antibiotic, rifabutin or high-dose metronidazole), to explore novel therapeutic strategies for patients with highly resistant H. pylori infections.",[27],[169,540,541],"Bismuth-Containing Quadruple Therapy","Drug Susceptibility Testing","2024-12-16",{"date":544,"type":32},"2024-12-19",{"date":546,"type":21},"2025-01-01",{"date":104,"type":21},{"name":549,"class":64},"Xiuli Zuo",{"id":551,"slug":552,"hasResults":11,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":92,"enrollmentInfo":557,"targetDuration":4,"studyType":22,"phases":559,"briefSummary":560,"conditions":561,"keywords":4,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":566,"leadSponsor":568,"locationsCount":40},"100571664","phase-4-efficacy-of-different-durations-of-dual-and-quadruple-regimens-for-helicobacter-pylori-eradication-100571664","NCT06723197","Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication","Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication: a Multicentre, Randomised, Controlled Trial","Inclusion Criteria:\n\n1. Patients aged 18-70 years old\n2. Patients with H.pylori infection (13C\u002F14C-urea breath test)\n3. Patients without previous treatment for H. pylori eradication\n\nExclusion Criteria:\n\n1. Patients with serious underlying diseases, such as liver insufficiency (Aspartate aminotransferase or alanine aminotransferase greater than the normal value), renal insufficiency (Cr≥2.0mg\u002FdL or glomerular filtration rate \\\u003C50 ml\u002Fmin), immunosuppression, malignant tumors, Coronary heart disease or coronary artery stenosis ≥75%\n2. Patients with active gastrointestinal bleeding\n3. Patients with a history of upper gastrointestinal surgery\n4. Patients allergic to treatment drugs\n5. Patients with medication history of bismuth, antibiotics within 4 weeks, or proton pump inhibitor within 2 weeks\n6. Patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial\n7. Patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse\n8. Patients who are unwilling or incapable to provide informed consents",{"count":558,"type":21},330,[142],"The study aimed to compare the efficacy and safety of dual and quadruple regimens with different durations (7-day, 10-day, 14-day) for the eradication of Helicobacter pylori. Subjects were randomized to receive the intervention and were reviewed by 13C-urea breath test after 6 weeks. The eradication rates, adverse reaction rates and patient adherence were calculated.",[27],"2024-12-10",{"date":564,"type":32},"2024-12-11",{"date":562,"type":32},{"date":567,"type":21},"2025-11-30",{"name":569,"class":64},"Shandong University"]